Incyte Gains 22.5% in Three Months, Beating Biotech Peers
Incyte (INCY) is up 22.5% in three months, beating XBI's 11%, after Q2 sales jumped 40.5% to $1.5 billion and management raised FY2026 guidance to $5.13–$5.26 billion.
Topic
Pharma
Topic
Pharma
Ex-Gilead Executive's Novel-Drug Startup Targets $1 Billion IPO Valuation
A startup founded by a onetime Gilead Sciences executive is pursuing an initial public offering at a $1 billion valuation, The Bu…